

1 **Full title:** Aberrant stromal tissue factor and mycolactone-driven vascular permeability,
2 exacerbated by IL-1 β , orchestrate pathogenic fibrin formation in Buruli ulcer lesions

3

4 **Short title:** Endothelial dysfunction in Buruli ulcer skin lesions

5

6 Louise Tzung-Harn Hsieh¹, Scott J Dos Santos^{1,#a}, Joy Ogbechi^{1,#b}, Aloysius D. Loglo^{1,#c},
7 Francisco J. Salguero², Marie-Thérèse Ruf^{3,4}, Gerd Pluschke^{3,4}, and Rachel E. Simmonds^{1,*}

8

9 ¹Department of Microbial Sciences, School of Bioscience and Medicine, University of Surrey,
10 Guildford, United Kingdom

11

12 ²Public Health England, Manor Farm Road, Porton Down, Salisbury, United Kingdom

13

14 ³Swiss Tropical and Public Health Institute, Basel, Switzerland

15

16 ⁴University of Basel, Basel, Switzerland

17

18 ^{#a} Current address: Western College of Veterinary Medicine, University of Saskatchewan,
19 Saskatoon, Canada

20

21 ^{#b} Current address: Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive,
22 Headington, Oxford, United Kingdom

23

24 ^{#c} Current address: Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame
25 Nkrumah University of Science and Technology, Kumasi, Ghana

26

27 * Corresponding author, email: rachel.simmonds@surrey.ac.uk

28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 **Author contributions**

30 Conceptualization: LTHH FJS RES. Performed the experiments: LTHH JO ADL MTR.
31 Analysed the data: LTHH SJDS JO FJS MTR RES. Contributed materials: MTR GP. Wrote
32 the manuscript: LTHH SJDS FJS MTR RES. Funding acquisition: GP RES.

33

34 **Abstract**

35 The neglected tropical disease Buruli ulcer, caused by *Mycobacterium ulcerans* infection,
36 displays coagulative necrosis in affected skin tissues. We previously demonstrated that
37 exposure to the *M. ulcerans* exotoxin mycolactone depletes the expression of thrombomodulin
38 and impacts anticoagulation at the endothelial cell surface. Moreover, while widespread fibrin
39 deposition is a common feature of BU lesions, the cause of this phenotype is not clear. Here,
40 we performed sequential staining of serial tissue sections of BU patient biopsies and unbiased
41 analysis of up to 908 individual non-necrotic vessels of eight BU lesions to investigate its
42 origins. Most vessels showed evidence of endothelial dysfunction being thrombomodulin-
43 negative, von Willebrand factor-negative and/or had endothelium that stained positively for
44 tissue factor (TF). Primary haemostasis was rarely evident by platelet glycoprotein CD61
45 staining. Localisation of TF in these lesions was complex and aberrant, including diffuse
46 staining of the stroma some distance from the basement membrane and TF-positive infiltrating
47 cells (likely eosinophils). This pattern of abnormal TF staining was the only phenotype that
48 was significantly associated with fibrin deposition, and its extent correlated significantly with
49 the distance that fibrin deposition extended into the tissue. Hence, fibrin deposition in Buruli
50 ulcer lesions is likely driven by the extrinsic pathway of coagulation. To understand how this
51 could occur, we investigated whether clotting factors necessary for fibrin formation might gain
52 access to the extravascular compartment due to loss of the vascular barrier. *In vitro* assays
53 using primary vascular and lymphatic endothelial cells showed that mycolactone increased
54 the permeability of monolayers to dextran within 24 hours. Moreover, co-incubation of cells
55 with interleukin-1 β exacerbated mycolactone's effects, nearly doubling the permeability of the
56 monolayer compared to each challenge alone. We propose that leaky vascular and lymphatic
57 systems are important drivers of extravascular fibrin deposition, necrosis and oedema
58 frequently seen in Buruli ulcer patients.

59

60 **Author Summary**

61 To date, the debilitating skin disease Buruli ulcer remains a public health concern and financial
62 burden in low or middle-income countries, especially in tropical regions. Late diagnosis is
63 frequent in remote areas, perhaps due to the painlessness of the disease. Hence patients
64 often present with large, destructive opened ulcers leading to delayed wound closure or even
65 lifelong disability. The infectious agent produces a toxin called mycolactone that drives the
66 disease. We previously found evidence that the blood clotting system is disrupted by
67 mycolactone in these lesions, and now we have further explored potential explanations for
68 these findings by looking at the expression of coagulation regulators in BU. In detailed analysis
69 of patient skin punch biopsies, we identified distinct expression patterns of certain proteins
70 and found that tissue factor, which initiates the so-called extrinsic pathway of blood clotting, is
71 particularly important. Mycolactone is able to disrupt the barrier function of the endothelium,
72 further aggravating the diseased phenotype, which explains how clotting factors access the
73 tissue. Altogether, such localised hypercoagulation in Buruli ulcer skin lesions may contribute
74 to the development of the lesion.

75 Introduction

76 Buruli ulcer (BU) is a neglected tropical disease, resulting from a subcutaneous infection with
77 *Mycobacterium ulcerans*, with approximately 2700 new cases reported globally in 2018
78 according to the latest update from World Health Organization (WHO) [1]. BU endemic areas
79 include West and Central African countries as well as Australia; globally over 30 countries
80 have reported cases with estimated prevalence ranging from 3.2-26.7 BU cases per 10,000
81 population [2, 3]. BU presents in various forms such as nodules, plaques, ulcers and oedema
82 [2]. In late diagnosed cases, necrotic skin lesions and soft tissue destruction can extend to
83 15% of body surface area, which may cause lifelong disability [4]. This debilitating skin
84 condition can be treated with dual anti-mycobacterial antibiotics, sometimes alongside surgical
85 removal of infected skin tissues [5]. Yet delayed wound healing rate remains a critical issue,
86 especially in patients bearing large, open lesions [6].

87
88 Histopathological analyses of BU patient biopsies reveal unique features of *M. ulcerans*
89 infections [7]. For instance, the coagulative necrosis seen in BU lesions displays a relative
90 paucity of leukocytic infiltration close to the bacilli themselves [7, 8]. Instead, neutrophils are
91 seen in the peripheral areas [9] and necrotic tissues often extend some distance from the site
92 of mycobacterial colonisation [7, 10]. Both characteristics are caused by the lipid-like exotoxin
93 produced by *M. ulcerans*, mycolactone [10, 11], which is synthesised by polyketide synthases
94 encoded on a megaplasmid, pMUM001 [12].

95
96 Mechanistically, mycolactone causes cell cycle arrest in G₀/G₁ and subsequent progression
97 to apoptosis after 48-72 hours, depending on cell type [10, 13]. Mycolactone can potentiate
98 an integrated stress response via eIF2 α phosphorylation and ATF4 activation [14, 15]. In
99 addition, mycolactone has immunosuppressive effects on the maturation or functions of
100 macrophages, dendritic cells and T cells [16-20]. All these activities can now be attributed to

101 mycolactone's inhibitory effect on Sec61 translocon [21, 22], which affects co-translational
102 translocation of proteins into the endoplasmic reticulum (ER) [21, 23-26]. This blockade leads
103 to protein translation in the wrong cellular compartment followed by their proteasomal
104 degradation [21] and activation of autophagy pathways [14, 27]. Cells carrying mutations in
105 the gene encoding Sec61 α are resistant to mycolactone-driven cytotoxicity, supporting this as
106 the primary target of mycolactone, at least at lower doses [14, 22, 23].

107

108 Mycolactone targeting of the Sec61 translocon is seen in various cell types, including
109 endothelial cells, which regulate many physiological functions related to blood vessel
110 homeostasis [21, 28]. Normally, endothelial cells form a monolayer that lines the lumen of
111 blood vessels or form the capillaries. This semi-selective barrier controls the passage of small
112 molecules and white blood cells into and out of the bloodstream [29, 30]. When blood vessels
113 are injured, platelets rapidly attach to the damaged sites on the endothelium via its binding
114 partner von Willebrand factor (vWF) [29, 31]. Secondly to platelet plug formation,
115 coagulation reinforces the plug by producing a fibrin mesh to hold it in place [29]. Fibrin clot
116 formation can be triggered by both contact activation on a negative-charged, damaged surface
117 or via the tissue factor (TF)-initiated extrinsic coagulation pathway. TF exposed from the sub-
118 endothelium binds to blood-borne factor VIIa and other clotting factors, leading to thrombin
119 activation and consequent processing of fibrinogen to fibrin [31]. These haemostatic pathways
120 are regulated by the endothelium through its expression of specific molecules that function in
121 anticoagulant pathways [30]. These include thrombomodulin (TM) and the endothelial cell
122 protein C receptor (EPCR) that activate the protein C anticoagulant pathway [30, 32], tissue
123 factor pathway inhibitor (TFPI) that suppresses the factor VIIa-TF complex and free factor Xa
124 activity [33], and heparan sulphate proteoglycans within the glycocalyx that bind antithrombin
125 to directly inhibit thrombin [34].

126

127 We previously showed that mycolactone depletes thrombomodulin and the EPCR from
128 primary human dermal microvascular endothelial cells (HDMECs) [28]. Reduced
129 thrombomodulin staining was also seen in clinical specimens of BU where it was associated
130 with fibrin deposition, itself strongly correlated with tissue necrosis [28]. While we did consider
131 the dermis and subcutis separately, we acknowledged challenges in the analysis due to tissue
132 heterogeneity. In order to overcome these challenges and to better understand the role and
133 origin of fibrin deposition in BU lesions, originally reported in the mid-20th Century, we
134 performed immunohistochemical staining of serial tissue sections of BU patient skin biopsies
135 for vascular and coagulation biomarkers. This more comprehensive analysis now shows an
136 unexpected paucity of platelets, even in areas with extensive fibrin deposition, and widespread
137 endothelial dysfunction. Fibrin deposition is explained by abnormal expression patterns of TF,
138 implicating the involvement of extrinsic clotting pathway. The largest effect was driven by
139 vessels that displayed TF staining at significant distance away from the basement membrane.
140 In parallel experiments, our *in vitro* data showed that mycolactone increased the permeability
141 of endothelial monolayers. Taken together our findings suggest that the vessels in BU lesions
142 may become “leaky” during infection due to loss of the endothelial barrier integrity, and that
143 this drives fibrin formation.

144 **Results**

145 Immunostaining was performed on serial skin biopsy tissue sections from 8 untreated,
146 laboratory confirmed BU patients (6 with ulcerative lesions and 2 with plaque, covering 3 WHO
147 categories; Table 1 and S1 Fig). Repeat staining for several markers on different sections of
148 the same punch biopsies in Ogbechi et al., 2015 [28] revealed that the pathology of Buruli
149 ulcer is highly focal, even within these small 4mm samples of infected skin (S2A Fig). Hence,
150 serial sections minimise drift throughout the biopsy sample and allow the tracking of individual
151 vessels within the skin (S2B Fig) between the sections. The sections were stained in the
152 following order: haematoxylin-eosin, fibrin, thrombomodulin (CD141), CD61, CD31 (Platelet
153 endothelial cell adhesion molecule; PECAM-1), smooth muscle actin (SMA), Ziehl-Neelsen,
154 TF and vWF. Regions of BU punch biopsy samples containing as many non-necrotic blood
155 vessels as possible were defined by a pathologist prior to the start of analysis. This decision
156 was made based on the number of blood vessels present that were positive for SMA or CD31
157 and whether there was any submacroscopic appearance of coagulative necrosis present in
158 the corresponding H&E section. These “pre-defined” regions (see methods) are outlined in red
159 in S1 Fig; nine areas were within the dermis and one area was located in the subcutis.
160 Quantitative analysis concerned all identifiable vessels within these regions, regardless of
161 whether nearby tissue displayed local signs of necrosis, in order to facilitate an unbiased
162 analysis. Qualitative comparative analysis of the novel biomarkers not yet explored in BU
163 (CD61, vWF and TF) was also performed across the whole biopsies, including areas that were
164 highly necrotic. Acid fast bacilli were only visible in the sections from two of the patients (S2C
165 Fig), therefore we do not report analysis of the coincidence of Ziehl-Neelsen staining further.

166

167 **Vasculopathy is evident in non-necrotic vessels of Buruli** 168 **ulcer lesions**

169 First, we closely analysed the phenotype of blood vessels in the defined regions of BU lesions
170 using three well-known perivascular and/or endothelial cell markers: CD31, SMA and

171 thrombomodulin. Since our previous studies showed that both thrombomodulin and, to a
172 lesser extent, CD31 could be depleted by mycolactone exposure [28], we took a conservative
173 approach and identified vessels which stained positively for SMA, or at least one of
174 thrombomodulin and/or CD31. Using this approach, a total of 908 vessels were identified in
175 the pre-defined regions of the eight patient samples (median of 92.5 vessels per patient
176 sample, range 18-253).

177

178 When vessels were categorised according to the expression of these three markers (any level
179 of positive staining), thrombomodulin presence was found to vary widely, regardless of the
180 lesion type or WHO Category. All the vessels in the pre-defined region of one patient displayed
181 were TM⁺ (Fig 1A), although for this patient the pre-defined region was very small and
182 contained only 18 vessels (S1 Fig). In contrast, two patients had few vessels expressing
183 thrombomodulin in the analysed areas, while other patients' samples showed intermediate
184 degrees of positive staining (Fig 1A). Overall, in the pre-defined regions containing non-
185 necrotic vessels, only 299 out of 908 (32.9%) had normal staining (TM⁺ CD31⁺ SMA⁺). The
186 remaining vessels lacked one or more of the expected vessel markers, with the most common
187 phenotypes being TM⁻ CD31⁺ SMA⁺ (37.4%) and TM⁻ CD31⁻ SMA⁺ (18.7%). Some of the singly
188 positive SMA structures could potentially be sweat glands with vessel-like morphology.
189 However, even if this is the case for a proportion of these solely SMA⁺ structures, the data
190 suggests a general vasculopathy in these BU lesions that precedes the emergence of
191 coagulative necrosis.

192

193 In order to understand whether the previously described association between thrombomodulin
194 depletion and fibrin deposition [28] is functionally linked, fibrin deposition was scored for each
195 identified vessel in the defined regions, according to its degree of extension. Here, 852 vessels
196 were trackable in analysed areas of tissue sections stained with fibrin, since not all vessels
197 identified above could be found in subsequent sections. As reported previously [28], fibrin

198 staining was seen across the biopsies, both in the defined regions and in highly necrotic areas
199 but varying in intensity and extent for each patient (S1 Fig). The fibrin was mostly evident as
200 tissue deposition surrounding, rather than in, blood vessels (298 vs. maximum 20 vessels in
201 the defined areas).

202

203 Scoring of the fibrin disposition around 329 TM⁺ and 523 TM⁻ vessels (where 0 is no staining,
204 and 3 is fibrin evident continuously for >30 μ m from the vessel) showed thrombomodulin
205 expression had no overall impact on fibrin levels (chi² vs normal staining pattern $P = 0.2007$,
206 Fig 1B). Hence, thrombomodulin depletion itself does not seem to be a good predictor of local
207 fibrin deposition. However, while most vessels were fibrin-negative, in vessels lacking
208 thrombomodulin expression the proportion with the highest fibrin score was increased
209 compared to TM⁺ vessels (13.0 vs. 7.3%, Fig 1B). Moreover, the fibrin intensity within 20 μ m
210 of vessels lacking TM expression was much more variable than those where TM was detected
211 (up to 79.0 vs. 45.8%, Fig 1C), suggesting the loss may aggravate fibrin formation in certain
212 subgroup(s) of vessels. This is borne out by comparing the intensity of staining in fibrin-positive
213 vessels, where TM⁻ vessels had significantly higher levels of fibrin within 20 μ m.

214

215 **Primary haemostasis plays only a minor role in BU skin** 216 **lesions, perhaps due to mycolactone-depletion of von** 217 **Willebrand factor from endothelial cells**

218 Since loss of thrombomodulin does not explain all the fibrin disposition seen in BU patient
219 lesions, other pathways that could lead to fibrin formation were explored. First, we examined
220 the localisation of molecules involved in primary haemostasis [30]. vWF is the primary
221 component of Weibel–Palade bodies, secretory granules that are released from endothelial
222 cells in response to activation or injury [35]. In healthy skin, vWF was present in endothelial
223 cells lining blood vessels as expected [36] (Fig 2A1-2 and S3A Fig). As others have observed
224 [37, 38], there is a relatively high stromal background for vWF staining due to its presence in

225 serum. By contrast, in BU lesions, detection of endothelial vWF was frequently reduced (Fig
226 2B1, black arrowheads) or staining was seen in the intravascular space instead (Fig 2B1-2,
227 black stars); rarely, vWF remained detectable in the endothelium (Fig 2B3, black arrow).

228

229 One of vWF's primary roles is to capture activated platelets, thus providing a rich negatively
230 charged surface for amplification of the blood coagulation cascade leading to fibrin formation.
231 Activated platelets express platelet glycoprotein IIb/IIIa (CD41/CD61), as their main receptor
232 for vWF and fibrinogen, and here we examined the expression of CD61, also known as integrin
233 $\beta 3$ [39]. Surprisingly, considering the wide abundance of fibrin in the lesion, very little CD61
234 staining was seen in BU lesions (Fig 2B4 and S1 Fig), even in areas with coagulative necrosis.
235 This suggests a minor role, if any for primary haemostasis in lesion formation.

236

237 To consider this more closely, we analysed the colocalisation of CD61 and vWF in BU patient
238 vessels. In the defined regions (Fig 2C1-6, 2D1-6), CD61 and vWF were barely detectable in
239 vessels, despite strong fibrin staining in the vicinity (Fig 2C4 and 2D4, blue and purple arrows).
240 In vessels that were positive for of least one of SMA, CD31 or thrombomodulin, none stained
241 positively for CD61. In necrotic regions in the subcutis, CD61 staining was occasionally seen
242 in areas where fibrin deposition was evident, in vessels that were CD31⁺ and TM⁻, colocalising
243 with vWF (Fig 2E1-6, red arrows).

244

245 We have already shown that platelet activation is not directly affected by mycolactone [28],
246 and the CD61 presence did not correlate with vWF in non-necrotic vessels. Therefore, we
247 postulated that this might be due to mycolactone-dependent depletion of vWF from endothelial
248 cells, and there is some evidence to support this from these BU patient samples. Of 734
249 trackable vessels in defined regions in BU lesions, only 24.8% retained a normal expression
250 pattern, with their endothelial monolayer stained positively for vWF (Fig 2B3 and 2F upper

251 panel). Instead, nearly half (47.4%) had completely lost vWF staining (vWF⁻) (Fig 2B1, 2C6,
252 2D6 and 2F upper panel). Intriguingly, 204 vessels (27.8%) displayed vWF staining within the
253 lumen of microvessels, in the intravascular space (Fig 2B1-2 and 2F upper panel). This pattern
254 of staining was particularly evident in BU patient punch biopsies in which the pre-defined areas
255 were heavily infiltrated with immune cells (S1 Fig, outlined in blue), representing 52.5% of
256 such vessels (Fig 2F, lower panel). However, fibrin scores were similar across all three
257 phenotypes of vWF expression in vessels (chi² vs normal staining pattern $P = 0.2882$ and
258 0.1280 for intravascular and vWF⁻, respectively Fig 2F), suggesting that none of these
259 phenotypes are directly related to fibrin formation.

260

261 Since vWF enters Weibel-Palade bodies via the secretory pathway and should be a Sec61-
262 dependent protein [35], we reasoned that the widespread depletion of vWF in BU lesions might
263 be related to the ability of the diffusible exotoxin mycolactone to inhibit the Sec61 translocon.
264 Hence, we visualised vWF in cultured primary HDMECs and human umbilical vein endothelial
265 cells (HUVECs) by immunofluorescence (Figs 2G and S3B Fig). Although the amount of vWF-
266 positive granules (presumptive Weibel-Palade bodies) varied from cell to cell, these were
267 greatly reduced after 24 hours exposure to mycolactone (Fig 2G). Furthermore, when we
268 quantified the level of vWF in conditioned medium from HDMECs by enzyme-linked
269 immunosorbent assay (ELISA), both basal and thrombin-induced vWF secretion was almost
270 completely abolished following mycolactone exposure (Fig 2H).

271

272 **Extravascular tissue factor within BU lesions correlates to** 273 **pathogenic fibrin deposition**

274 Another potential trigger for fibrin generation is activation of the extrinsic coagulation cascade,
275 initiated by TF. In the skin of healthy individuals, normal TF staining is found only in the
276 epidermis and the adventitia of larger (but not smaller) blood vessels as expected (Fig 3A1-2
277 and S4A Fig). This highly restricted expression pattern is vital to maintain intravascular fluidity,

278 due to its ability to rapidly catalyse activation of the coagulation cascade by binding Factor
279 VII/VIIa. In BU patient lesions, TF staining was not confined to the sub-endothelium and was
280 instead seen within the tissues in a complex, highly variable pattern between patients. For
281 example, in one patient, TF was present at the edge of damaged area (S4C Fig) where
282 extravasated erythrocytes had accumulated. Abnormal TF staining fell into one of four main
283 categories. First, staining outside of the vessel basement membrane (BM) of larger vessels
284 (Fig 3B5 and 3C5, red arrows). Second, in presumptive infiltrating cells, either demonstrating
285 granular intracellular staining (Fig 3D5 and S4B Fig, black arrows) or intensively throughout
286 each cell (Fig 3E5, black arrows). This pattern of staining was seen in both necrotic and in
287 defined regions, and in the latter case was in regions that appeared to contain eosinophils
288 based on Haematoxylin and eosin (H&E) staining (Fig 3E3, black arrowhead). Third, TF
289 staining was found within the endothelial cells lining smaller vessels (Fig 3F5, orange arrow),
290 which do not normally express this receptor. Lastly, some vessels contained some structures
291 within the vessel lumen that could not be identified, yet stained strongly for TF (Fig 3G5, purple
292 arrows). Approximately one quarter of vessels with this phenotype were in infiltrated regions
293 (Fig 3G3).

294

295 With respect to TF-positive presumptive-infiltrating cells, these were observed within tissue
296 rather than close to vessels. Granular intracellular staining was seen in 5 of the 8 BU patient
297 biopsies, almost exclusively in the defined regions where they were between 2.2-89.9 μm
298 away from the vessel BM. In most of these patients (4 out of 5) it occurred in areas displaying
299 fibrin deposition (compare Figs 3D4 and 3D5). Infiltrating cells displaying intensive TF-positive
300 staining throughout each cell body were seen in 6 of the 8 BU biopsies and always in regions
301 of fibrin accumulation. This phenotype was more common in the necrotic subcutis (5 patients).
302 In the one patient where it was seen in a defined region, the cells were 17.1-120.9 μm away
303 from the vessel BM.

304

305 Vessels in defined regions were tracked and classified according to their TF expression
306 patterns. Of 830 trackable vessels, 18.2% showed normal TF expression in the adventitia, 45
307 (5.4%) showed TF staining outside of the vessel BM, within the skin tissue, 63.3% displayed
308 abnormal TF staining in the vessel endothelium, and 13.1% showed TF within the vessel
309 lumen (Fig 3H). All abnormal expression patterns were associated with an increased chance
310 of having the highest fibrin score. While this was not significantly different for vessels where
311 TF staining was seen in the lumen (χ^2 vs normal staining pattern $P = 0.5901$), it was distinct
312 in vessels where the endothelium was TF⁺ (χ^2 vs normal staining pattern $P = 0.0014$). Most
313 strikingly, whilst being relatively rare in the defined regions, vessels that displayed TF staining
314 outside of BM were significantly more likely to have fibrin deposited in the surrounding tissue,
315 (χ^2 vs normal staining pattern $P < 0.0001$, Fig 3H) and more likely to have fibrin that extended
316 further from the vessel (82.22% exhibiting the highest fibrin score). Notably the coincidence of
317 fibrin and TF outside the BM was often found where there were local signs of tissue necrosis
318 by H&E staining (e.g. Fig 3C3), suggesting that fibrin-deposition may cause result directly in
319 necrosis, presumably due to ischaemia.

320

321 **Mycolactone reduces the expression of tissue factor** 322 **pathway inhibitor in endothelial cells**

323 The interaction between TF and the 50 kDa blood-borne factor VIIa, and the subsequent
324 triggering of the coagulation cascade leading to fibrin formation is normally prevented by a
325 functional endothelial barrier which segregates bloodstream from the TF-containing
326 subendothelium [30]. Normally, TF/factor VIIa activity is suppressed by TFPI, which is mostly
327 expressed by vascular endothelium and megakaryocytes [33]. Endothelial cells predominantly
328 express the membrane-associated TFPI splice variant lacking both the C-terminus and the
329 third Kunitz-type inhibitory domain (isoform β), but also express full-length TFPI (isoform α).
330 Upon stimulation or heparin infusion, TFPI α , bound to cell-surface glycosaminoglycans
331 through its C-terminus, can be secreted rapidly [40]. As fibrin deposition was found in BU

332 affected tissues and correlated to TF seen outside of vessel BM, we wondered whether TFPI
333 expression might be affected by mycolactone. As we were unable to test this in the biopsies
334 themselves, we investigated this *in vitro*. TFPI was rapidly depleted from HDMECs in response
335 to mycolactone exposure with a decrease detectable after 8 hours by Western blot (Fig 4A);
336 given that TFPI α and β have different levels of glycosylation and migrate with similar molecular
337 mass on sodium dodecyl sulfate polyacrylamide gel electrophoresis [41], we couldn't
338 distinguish between these isoforms. Quantification of this data demonstrated a 57.4%
339 reduction of total TFPI after 8 hours of mycolactone exposure and further to 88.3% after
340 24hours (Fig 4A). A similar decline was seen in conditioned medium, where the amount of
341 TFPI secreted by HDMEC over 24 hours reduced from 4.59 ± 0.18 to 0.74 ± 0.13 ng/mL (Fig
342 4B).

343

344 **Mycolactone-dependent vascular permeability as a** 345 **potential driver of coagulopathy in Buruli ulcer lesions**

346 Taken together the data from BU punch biopsies suggests that the expression of haemostatic
347 markers on the vessel endothelium is not a reliable predictor of fibrin deposition close to that
348 vessel. Instead, fibrin deposition in the tissue seems to arise locally and driven by TF
349 expression that is uncontained within the stroma. To examine how uncontained TF may impact
350 fibrin deposition in such a distinct phenotype, the staining intensity of TF and fibrin were
351 quantified and the distance of the TF signal from the vessel BM were measured in these same
352 vessels. There was no correlation between fibrin and TF staining intensity within 20 μ m ($r = -$
353 0.1623 , $P = 0.2869$) (Fig 5A). However, there was a positive correlation ($r = 0.2981$, $P =$
354 0.0467) between fibrin intensity and the distance of TF⁺ signal from the same analysed vessel
355 BM (Fig 5B).

356

357 Generation of fibrin within tissue, a substantial distance away from vessels, resulting from
358 extrinsic coagulation pathway activation would require large plasma glycoproteins to gain

359 access to the stromal compartment. We therefore asked whether mycolactone might induce
360 changes to vascular permeability that could lead to a breakdown of vessel integrity *in vitro*.
361 Hence, we evaluated the effect of mycolactone on the permeability of HDMEC monolayers to
362 70 kDa FITC-labelled dextran in a transwell system. In line with our hypothesis, exposure to
363 10 ng/mL mycolactone for 24 hours increased the permeability of the monolayer to $33.1 \pm 6.2\%$
364 of the value seen when cells were completely absent from the transwell (Fig 5C), equivalent
365 to around one-third of that seen with interleukin-1 β (IL-1 β), a known inducer of vascular
366 permeability [42].

367
368 We also wondered whether this mycolactone-dependent increase in permeability might extend
369 to the lymphatic system, since BU can sometimes have an oedematous presentation. In
370 human dermal lymphatic endothelial cells (HDLECs), a subpopulation of endothelial cells that
371 actively participate in fluid balance and transport [43, 44], this phenotype was even more
372 apparent. HDLECs and HDMECs had comparable half maximal inhibitory concentration to
373 mycolactone (around 0.67 ng/mL, S5 Fig), but the response of lymphatic endothelial cells to
374 mycolactone was more pronounced. Exposure to 10 ng/mL mycolactone for 24 hours
375 increased the permeability of the monolayer to $68.6 \pm 19.8\%$ of the value seen in empty wells
376 (Fig 5D). In the same time window, 2.5 ng/mL mycolactone could potentiate this effect but to
377 a lesser degree ($26.7 \pm 2.8\%$, Fig 5D).

378

379 **IL-1 β aggravates mycolactone-driven endothelial** 380 **dysfunction**

381 Recent work showed that IL-1 β can be induced by mycolactone-containing microvesicles and
382 is found in *M. ulcerans*-infected tissues [45]. Since IL-1 β has been long-known to repress
383 thrombomodulin expression in endothelial cells by a transcriptional mechanism [46], and also
384 induces vascular permeability [42], we wondered whether the presence of this alarm cytokine
385 might exacerbate the effect of mycolactone on the microvasculature. First, we addressed

386 whether mycolactone's ability to suppress thrombomodulin expression in primary endothelial
387 cells might be influenced by IL-1 β , by exposing cells to a range of concentrations of
388 mycolactone and/or IL-1 β . As expected, exposure to either 10 ng/mL IL-1 β or 2.5 ng/mL
389 mycolactone alone for 24 hours led to a significant depletion in thrombomodulin protein level
390 in both HDMECs (Fig 6A) and HDLECs (Fig 6B). Similar to our observations regarding
391 vascular permeability, lymphatic endothelial cells were more sensitive to both stimuli, with
392 >50% reduction in the presence of 0.6 ng/mL IL-1 β ($P = 0.0132$) or 1.25 ng/mL mycolactone
393 ($P = 0.0004$) (Fig 6B). Remarkably, this downward trend was more evident when the
394 endothelial cells were co-exposed to non-saturating amounts of both agents (Fig 6A and B).
395 For example, in HDMEC, while each stimulus alone resulted in ~55-75% depletion of
396 thrombomodulin expression, it was barely detectable in endothelial cells exposed to both 2.5
397 ng/mL mycolactone and 10 ng/mL IL-1 β . In HDLEC, the combination of 0.625 ng/mL
398 mycolactone and 0.6 ng/mL IL-1 β suppressed thrombomodulin expression to the same extent
399 as 10 ng/mL IL-1 β . These effects appear to be additive rather than synergistic.

400

401 Since the additive effect was particularly evident in HDMECs, we investigated whether it might
402 also influence vascular permeability in these cells. Here, we used a lower dose of IL-1 β , which
403 only slightly increased the permeability of monolayer after 24 hours ($7.66 \pm 3.89\%$ of the value
404 seen in an empty well, Fig 6C). Mycolactone had a dose-dependent effect on vascular
405 permeability as before, and the additive effect of IL-1 β was evident when there was 5 ng/mL
406 mycolactone, increasing the permeability significantly from $17.58 \pm 7.57\%$ to $44.62 \pm 9.65\%$ (P
407 = 0.0021 vs. DMSO; $P = 0.0268$ vs. mycolactone alone). This data suggests that even low
408 amounts of IL-1 β in infected tissues might have a further negative impact on haemostatic
409 status and endothelial monolayer integrity where trace amounts of mycolactone are present.

410 Discussion

411 Coagulation is often considered as a frontline host defence response to infection due to
412 trapping of invading bacteria clots [47]; however, some pathogens develop strategies to
413 bypass or utilise clot architecture to gain access to host resources. For example, *Streptococci*
414 generate streptokinase, a plasminogen activator mimic, that promotes fibrinolysis and thus
415 has a positive impact on bacterial metastasis [48]. Coagulase-positive *staphylococci*, on the
416 other hand, produce coagulase, which rapidly depletes fibrinogen from the plasma and blunts
417 the phagocytic activity of neutrophils [49]. Malaria-infected erythrocytes cause the loss of
418 EPCR and thrombomodulin in brain vessels, leading to subsequent fibrin deposition within the
419 microvasculature [50], which impacts the severity of cerebral malaria [51]. In the case of BU,
420 the skin lesions exhibit large-scale coagulative necrosis in the subcutaneous regions, a distinct
421 pathological phenotype, which has been long associated with the biological effects of the
422 exotoxin mycolactone as it diffuses through the infected tissue [52].

423

424 Cumulative reports with *in vitro* or *in vivo* assays have addressed how cell death can be
425 potentiated in response to mycolactone, either directly via the activation of caspase-3,
426 caspase-9 [53] or Bcl-2-like protein 11 [54] with resultant apoptosis, and/or via an integrated
427 stress response leading to ATF4 activation [14, 15]. These pathways may also involve
428 disruption of actin cytoskeleton [55]. More recently an indirect mechanism was proposed, via
429 mycolactone's Sec61-dependent influence on coagulation control and resultant tissue
430 ischemia [28]. However, to what extent coagulation is dysregulated in BU has been unclear.
431 This present work demonstrates several abnormal phenotypes for haemostatic proteins in the
432 dermal microvasculature of BU patients that includes: 1) loss of key endothelial proteins such
433 as the endothelial adhesion molecule CD31, the anticoagulant thrombomodulin, and the
434 platelet binding partner vWF, and 2) highly abnormal expression patterns of TF that suggest
435 a loss of containment. These changes likely underpin the pathogenic fibrin deposition seen in
436 the skin lesions and imply that infection with *M. ulcerans* may cause a localised, disturbed

437 haemostatic status. This conclusion is reinforced by *in vitro* data using primary endothelial
438 cells, in which we show that mycolactone can potentiate vascular and lymphatic hyper-
439 permeability. Moreover, mycolactone limits the expression, and secretion of, vWF and TFPI.

440

441 Mechanistically, a combination of mycolactone's action at the Sec61 translocon, and
442 increased local concentration of IL-1 β , likely explains the endothelial dysfunction seen in BU.
443 Like the single-pass type I membrane proteins thrombomodulin and CD31 [28], the secretory
444 proteins vWF and TFPI require Sec61-dependent co-translational translocation into the ER
445 lumen to complete their biosynthesis, processes that are inhibited by mycolactone [24, 25]. In
446 *in vitro* model systems, the mycolactone concentration is uniform, whereas in BU skin lesions
447 the situation is more complicated, but where mycolactone is present at high enough
448 concentrations, depletion of these Sec61-dependent molecules should also occur as the
449 process is conserved amongst diverse cell types. The variations in endothelial marker
450 expression seen in different specimens and sections from the same specimen may therefore
451 reflect local variations in mycolactone concentration. However, while there is much evidence
452 for mycolactone within BU lesions [10, 56], these currently lack the spatial resolution to
453 understand exactly how much mycolactone is present at specific sites.

454

455 It is clear from our data that in the complex structure of the disordered skin in BU that there
456 was less than expected correlation between loss of endothelial transmembrane proteins,
457 based on Sec61 inhibition alone. For instance, while many vessels lost both thrombomodulin
458 and vWF, some had lost expression of one marker but not the other. Since it was recently
459 shown that IL-1 β is present in BU skin lesions also with variable intensity across biopsy
460 samples [45], we tested the hypothesis that this may add an additional layer of complexity in
461 the *in vivo* setting. We showed that mycolactone and IL-1 β have an additive effect *in vitro*,
462 suggesting that the variation in marker expression could be caused by the cumulative effect
463 of local mycolactone and IL-1 β . In this context, it is also worth noting that the distance between

464 our serial tissue sections for these markers is 24 μm inclusive and given the focal nature of
465 the staining for the same markers across the section (see Fig S2A), this could also be a
466 contributing factor.

467

468 These BU patients showed widespread changes to the localisation of vWF in skin punch
469 biopsies, with only a minority of vessels in defined regions displaying a normal expression
470 pattern. In healthy tissue, vWF is expressed solely in endothelial cells, and is found contained
471 within organelles called Weibel-Palade bodies (WBPs), which also contain a variety of other
472 components regulating inflammation as well as vascular modulators [57]. Endothelial cells
473 respond rapidly upon activation by a variety of so-called secretagogues to exocytose their
474 WBP, upon which the vWF forms multimeric strings of molecules whose normal function is to
475 capture platelets [58]. It is possible that WBP exocytosis explains the pattern we observed,
476 particularly in immune cell infiltrated regions, where vWF was lost from endothelial cells and
477 instead observed in the adjacent intravascular space. This pattern of expression has been
478 previously reported in the dermal vasculature of patients with malignant melanoma [59] as
479 well as alveolar septa and large blood vessels of patients with malaria-associated acute
480 respiratory distress syndrome [37]. In melanoma vasculatures, CD42⁺ platelet aggregates
481 were also seen bound to intravascular vWF fibres [59], due to an endothelial glycocalyx
482 shedding-dependent process [60]. We did not observe platelet aggregates in these vessels in
483 our BU patients, although we cannot completely rule out that this is a technical limitation of
484 the antibody used to detect them [61].

485

486 Another haemostatic factor with a grossly abnormal expression pattern was the extrinsic
487 pathway initiator TF, which plays a critical role in both fibrin generation and wound repair [62].
488 Exposure of TF to blood is sufficient to initiate clotting, due to its cofactor activity in the
489 activation of factors IXa and Xa by factor VIIa [63]. Consequently, TF expression in the skin is
490 normally restricted to the epidermis and the adventitia surrounding larger vessels as a so-

491 called “haemostatic envelope” [63], and its activity is usually tightly regulated by an inhibitor,
492 TFPI [33]. Changes in TF expression have been reported in many inflammatory thrombotic
493 conditions [62, 64], as well as in infections such as tuberculosis [65, 66]. Myeloid cells do not
494 normally express TF, but during *M. tuberculosis* infection, TF expression is observed in
495 macrophages along with conspicuous fibrin deposition within granulomas [66, 67]. Mice
496 genetically altered to have low TF expression [65] or TF deficiency in myeloid cells [67] do not
497 show these changes.

498

499 Whether the endothelium can be a cellular source of the TF in pathogenic conditions remains
500 highly controversial [62, 68]. It is well-established that inflammatory agents such as
501 lipopolysaccharide, oxidized low density lipoprotein and IL-1 β can induce TF mRNA and
502 protein expression in monocytes and macrophages both *in vitro* and *in vivo* [69-71]. On the
503 other hand, while endothelial cells can be induced to express TF *in vitro* in response to
504 lipopolysaccharide and IL-1 β [42, 72, 73] the evidence that this takes place *in vivo* as part of
505 a pathophysiological process is not so clear. For instance, endothelial-specific TF-knockout
506 mice display little influence over pathogenesis in a range of disease models [62, 74]. Much
507 evidence supports a view that procoagulant TF always arises via activated mononuclear cells
508 and that the detection of TF in other cells is a consequence of microparticle uptake [62, 75].
509 Indeed, early reports that eosinophils could express TF following activation [76] were more
510 recently shown to be explained by their uptake of monocyte-derived microparticles [68]. While
511 this is a highly complex and also controversial area, many cell types including endothelial cells,
512 platelets, and monocytes/macrophages have all been shown to be capable of producing TF-
513 bearing microparticles *in vitro*, but monocyte-derived microparticles have been shown to be
514 the most thrombogenic [77]. As well as providing the extrinsic clotting pathway initiator TF,
515 microparticles are also thought to promote coagulation by providing a rich negatively charged
516 surface for the amplification of the coagulation cascade at their location [62]. The presence of
517 circulating TF-bearing microparticles has been reported in patients with cancer-associated

518 thrombosis [78], venous thromboembolism [79], cardiac bypass surgery [80], Behçet's disease
519 [81] and sepsis [82].

520

521 In the BU patients we investigated, epidermal expression of TF was not altered, but within the
522 dermis and subcutis extremely disordered TF expression was observed. In stark contrast to
523 healthy skin, even in the pre-defined regions containing non-necrotic vessels, TF was detected
524 in the endothelial cells of >60% of tracked vessels, as well as in infiltrating cells in five patients
525 with either granular, or one patient with whole-cell, staining. This finding, reminiscent of
526 inflammatory thrombotic conditions, such as sepsis and atherosclerosis [62, 64, 68], was
527 surprising because of mycolactone's well-characterised immunosuppressive and anti-
528 inflammatory effects [56]. Once again, IL-1 β may play an important role here. We speculate
529 that the TF⁺ endothelial cells and presumptive eosinophils we observed could have arisen by
530 uptake of TF-bearing microparticles induced by IL-1 β within the lesions. It is unlikely that TF
531 in the endothelium has much influence over disease progression in these BU patients, as fibrin
532 deposition was little altered around these vessels even when the anticoagulant
533 thrombomodulin was also lost from the endothelial cell surface. On the other hand, we
534 observed TF⁺ cells (presumably eosinophils) in necrotic and, more rarely, regions of BU
535 lesions containing plentiful non-necrotic vessels, where fibrin was seen intensively in tissues.
536 Notably, eosinophils have also been reported as the cellular source of TF seen in another skin
537 condition, chronic urticaria [83]. It is also possible that some of the infiltrating TF⁺ cells we
538 observed are activated macrophages that have been induced to express TF. *M. ulcerans*
539 infection is known to include a phase where macrophages are transiently infected with bacteria
540 [84], and the death of these cells due to the cytotoxic effects of mycolactone could conceivably
541 be another source of microparticles. Whether microparticles of any origins play an important
542 role in BU will be the subject of future investigations.

543

544 The strongest association we observed with fibrin deposition was diffuse TF staining extending
545 away from larger vessels, up to 200 μm into tissue. A key question that arose was; how do TF
546 and the other plasma clotting factors required to produce thrombin and consequently process
547 fibrinogen to fibrin access these sites? Using an *in vitro* vascular permeability assay, we
548 showed that mycolactone potentiates the passage of 70 kDa-size dextran through monolayers
549 of both HDMECs and HDLECs. Given that adhesion molecules such as CD31 [85],
550 thrombomodulin [86, 87] and vascular endothelial cadherin are essential regulators for
551 endothelial tight junctions, and these proteins are downregulated by mycolactone [28], a
552 disturbed endothelial physical barrier between plasma and tissue could be an unavoidable
553 phenotype in BU. A leaky vasculature is well-established to result in increased immune cell
554 invasion, as well as allowing plasma components and fluids to enter tissue [88, 89]. Hence,
555 the disrupted physical barrier may initiate a clotting cascade as blood-borne clotting factors
556 engage with their sub-endothelium located binding partners or activators [90].

557

558 Inflammatory cytokines are known to affect both microvascular and lymphatic endothelial
559 barriers and augment vascular permeability [88, 91], and this can cause tissue oedema in
560 many disease conditions [29, 88, 91]. In BU, oedematous forms are seen in around 5% of
561 patients [92]. Further work will be required to establish how early in the infection process
562 vascular permeability increases, and to understand whether it has a direct impact on *M.*
563 *ulcerans* growth. Mycolactone's effect on vascular permeability *in vitro* occurred much earlier
564 (within 24 hours) than its cytotoxic effects (more than 72 hours in HDMECs) and at an
565 extremely low dose (10 ng/mL), even lower in the presence of small amounts of IL-1 β .
566 Furthermore, while increased vascular permeability is a common strategy used by innate host
567 defence systems to fight against invading microorganisms, many pathogens also target cell-
568 cell junctions in order to cross the barrier and colonise in tissues. Interestingly, *Mycobacterium*
569 *marinum*, a close genetic relative of *M. ulcerans*, targets vascular integrity to aid its
570 multiplication in granulomas [89].

571

572 Taken together, both our cell-based studies and histopathological analysis in patient
573 specimens illustrate a hypercoagulative microenvironment that develops during BU disease
574 progression. It seems likely that the fibrin deposition seen in BU skin punch biopsies is not
575 driven by platelet aggregation; instead, it is likely to be the consequence of factor VIIa
576 engaging with sub-endothelial TF as the endothelial cell monolayer integrity is disturbed,
577 exacerbated by the loss of its natural inhibitor TFPI. We have not yet analysed any potential
578 contribution of the intrinsic clotting pathway; therefore, this cannot be excluded. A correct
579 balance of the TF-driven coagulation cascade and subsequent fibrin formation is critical in
580 wound healing [93]. Hence, application of anticoagulants along with antibiotics could help
581 neutralise the pro-thrombotic phenotype seen in BU patient skin lesions, and ultimately
582 improve healing rate. Of note, complementary anticoagulant heparin alongside standard anti-
583 tubercular antibiotics treatment has been previously employed to treat a case of facial BU. In
584 this patient, facial oedema was reversed by heparin intravenous injection [94], suggesting
585 lowering haemostatic status may attenuate BU disease progression.

586 **Materials and Methods**

587

588 **Ethics statement**

589 Ethical approval for analysing BU patient punch biopsies was obtained from the
590 Ethikkommission beider Basel, Basel, Switzerland and the provisional national ethical review
591 board of the Ministry of Health Benin (N IRB00006860) as well as from the Cameroon National
592 Ethics Committee and the Ethics Committee of the Heidelberg University Hospital, Germany
593 (ISRCTN72102977). A favourable ethical opinion for analysing normal human skin was given
594 by Faculty of Health and Medical Science Ethics Committee of the University of Surrey (1174-
595 FHMS-16). The normal human skin samples were collected by the Whiteley Clinic, Guildford,
596 Surrey or were purchased from AMS Biotechnology. Written informed consent was obtained
597 from adult patients or the guardians of child patients. The research related to human tissues
598 complies with the ethical processes of University of Surrey.

599

600 **Histological analysis of human skin samples**

601 Buruli ulcer punch biopsies (4 mm) were collected previously [95] and reanalysed for the
602 current study. The biopsies from 4 male and 4 female patients included lesions on both the
603 upper and lower extremities, from all WHO lesion categories [1]. Clinical features of these
604 patients are summarised in Table 1. In BU patients displaying ulcerated lesions, punch
605 biopsies were taken 1 cm inside the outer margin of the induration surrounding the ulcer.
606 Otherwise, punch biopsies were collected from the non-ulcerated centre of the skin lesions.
607 After removal, tissues were fixed in 10% neutral buffered formalin, transported, embedded in
608 paraffin and sectioned. The normal human skin tissue blocks were made from 4 mm punch
609 biopsies collected by The Whiteley Clinic or surgical removal specimens (< 1cm²) collected by
610 AMS Biotechnology-collaborated research clinical centres.

611

612 Nine serial tissue sections of each patient were (immuno-)histochemically stained in the
613 following order: haematoxylin-eosin, fibrin, thrombomodulin (CD141), CD61, CD31 (Platelet
614 endothelial cell adhesion molecule; PECAM-1), SMA (perivascular cell marker), Ziehl-
615 Neelsen, TF and vWF. For immunohistochemical staining, 5- μ m skin tissue sections were
616 deparaffinised, endogenous peroxidase quenched, epitope unmasked (either in preheated pH
617 6 citrate buffer or treated with proteinase K, DAKO) and blocked with normal horse serum
618 (Vector Laboratories). The tissue sections were incubated with primary antibody overnight at
619 4°C and biotin-conjugated horse anti-mouse/ rabbit IgG (Vector Laboratories) for 30 minutes
620 at room temperature. Primary antibodies were as follows: CD31 (M0823, DAKO),
621 thrombomodulin (M0617, DAKO), SMA (NCL-SMA, Novocastra), CD61 (M0753, DAKO), vWF
622 (ab6994, Abcam), TF (TF218; generous gift from Professor Wolfram Ruf, Scripps Research
623 Institute) and Fibrin (59D8 [96]; generous gift from Professor Charles Esmon, Oklahoma
624 Medical Research Foundation). Staining was performed using VECTASTAIN Elite ABC kit and
625 Vector NovaRED peroxidase substrate (Vector Laboratories). Counterstaining was performed
626 with Shandon Harris Haematoxylin (Thermo Fisher Scientific). Anti-TF and vWF antibodies
627 and their respective matched isotype controls were introduced to healthy skin tissue slides to
628 rule out unspecific signals. High resolution images of all slides were scanned using either
629 Aperio slide scanner (Leica Biosystems), Panoramic digital slide scanners (3DHISTECH) or
630 Hamamatsu slide photometry system (Hamamatsu Photonics). Scanned images were further
631 analysed using ImageScope software (Leica Biosystems) or CaseViewer (3DHISTECH). In
632 some cases, photographs were taken with Micropix microscope camera (acquisition software
633 Cytocam) attached to a Yenway CX40 laboratory microscope (Micropix).

634

635 **Vessel identification and marker analysis**

636 Regions of BU punch biopsy samples containing as many non-necrotic blood vessels as
637 possible were defined by a pathologist prior to the start of analysis. This decision was made
638 based on the number of blood vessels present that were positive for SMA or CD31 and

639 whether there was any submacroscopic appearance of coagulative necrosis present in the
640 corresponding H&E section. Two patient biopsies showed two distinct regions that contained
641 plentiful non-necrotic blood vessels, therefore a total of ten representative areas were
642 analysed for each biomarker. Once the regions were chosen, all blood vessels within them
643 were analysed, regardless of whether nearby tissue displayed local signs of necrosis, in order
644 to facilitate an unbiased analysis. Throughout this manuscript, we refer to these as “pre-
645 defined” regions. Vessels within these pre-defined regions were initially identified by
646 morphology and positive staining for SMA using the region of interest (ROI) tool on NIS
647 Elements Basic Research (Nikon, Tokyo, Japan) (version 4.6). This allowed for the same
648 vessels to be easily identified in the other sections. Any structure that had vessel morphology
649 and that stained positively for the known endothelial markers CD31, thrombomodulin, or vWF
650 in their corresponding sections were also identified and then tracked in the corresponding
651 sections. Sweat glands stain for SMA, but do not have endothelium and do not stain for CD31,
652 thrombomodulin or vWF [97, 98], therefore the morphology of singly SMA⁺ structures were
653 carefully considered before assigning them as vessels. Fibrin deposition and TF expression
654 pattern around these vessels, if identifiable, was categorised. Note that not every vessel could
655 be identified within all sections, therefore the number of vessels analysed always represents
656 the number that could be identified through all the relevant sections, and therefore varies from
657 analysis to analysis.

658

659 To analyse fibrin deposition that was largely seen within the tissues, two different approaches
660 were taken. First, the distance that fibrin staining extended from the basement membrane was
661 categorised based on measurements taken with Aperio ImageScope (version 12.3.3). Vessels
662 with no fibrin staining within 20 μm were scored as 0. Fibrin-positive vessels received
663 increasing scores the further the staining extended (1; <20 μm radius, 2; 20-30 μm radius, 3;
664 >30 μm radius). Second, fibrin staining around each vessel was quantified using the calibrated
665 ruler tool of NIS Elements Basic Research (version 4.6 and 5.21.01). Here, the threshold for

666 positive staining was first defined within random images, which was then applied to all vessels.
667 Then, a 20 μm area around all vessels was measured and traced again with the ROI tool. The
668 area of each original vessel was subtracted from the area of its 20 μm radius in order to give
669 the area in which fibrin staining was to be quantified. Any staining within this was then
670 calculated as a percentage of the 20 μm area around each vessel.

671

672 To analyse the unusual TF staining pattern observed, TF staining intensity within 20 μm was
673 quantified as above for fibrin using the calibrated ruler tool of NIS Elements Basic Research
674 (version 5.21.01). In addition, the distance that the TF signal extended from the individual
675 vessel's basement membrane was measured by CaseViewer (version 2.2).

676

677 **Reagents**

678 Synthetic mycolactone A/B (generous gift of Professor Yoshito Kishi, Harvard University) [99]
679 and its solvent control dimethyl sulfoxide (DMSO, Sigma) were used in cell-based studies.
680 Human recombinant IL-1 β was from Gibco.

681

682 **Cell culture and treatment**

683 Primary human dermal microvascular endothelial cells (HDMEC; LONZA), human umbilical
684 vein endothelial cells (HUVECs, PromoCell) and human dermal lymphatic endothelial cells
685 (HDLEC; PromoCell) from two donors were used and cultured according to manufacturer's
686 recommendation in Endothelial cell growth medium MV2 (PromoCell). Subconfluent cells were
687 treated with either 10 ng/mL mycolactone or DMSO equivalent to mycolactone dose for 24 hrs
688 or as indicated in figure legend.

689

690 **Vascular permeability assay**

691 Endothelial cells were seeded on cell culture inserts containing 0.4 (Millipore) or 1 μm pores
692 (Falcon) with a polyethylene terephthalate membrane. Cells were treated as indicated, into
693 both the insert and receiver wells. After 24 hrs, fluorescein isothiocyanate (FITC)-conjugated
694 dextran (70 kDa, Millipore) was applied to each insert for 20 minutes. The fluorescence
695 intensity of the solution in the lower chambers was then assessed by a fluorescent plate reader
696 (FLUOstar Omega, BMG Labtech) with excitation/ emission wavelength at 485/ 530 nm.
697 Fluorescence intensity was normalised to untreated control wells with an intact monolayer of
698 endothelial cells (minimum) and expressed as a percentage of subtracted value obtained from
699 wells where the insert had no cells (maximum).

700

701 **Cell viability assay**

702 Endothelial cells (4×10^3 cells) were seeded onto 96-well plates and treated with a variety of
703 doses of mycolactone the following day. Serial dilutions of mycolactone from 50 to 0.098
704 ng/mL or solvent control equivalent to highest mycolactone dose (0.1% DMSO) was applied
705 to the cells; on the fifth day viability was assayed using alamarBlue Cell Viability Reagent
706 (Invitrogen) with excitation/ emission wavelength at 560/ 590 nm by a plate reader (FLUOstar
707 Omega, BMG Labtech). Values were normalised to the control wells treated with DMSO and
708 are presented as survival rate (%).

709

710 **Immunochemical analysis**

711 Western blot analysis was carried out using standard techniques, following cell lysis with 1X
712 RIPA buffer (Sigma) supplied with proteinase inhibitor cocktail (Sigma), separation by
713 electrophoresis on 10% polyacrylamide gels and transfer to PVDF membranes (ThermoFisher
714 Scientific). Antibodies used were TM (sc-13164, Santa Cruz), TFPI (AF2974, R&D Systems)
715 and GAPDH (AM4300, Ambion). Immunofluorescence staining was performed on

716 paraformaldehyde-fixed cells after permeabilising with 0.5% Triton X-100 for 2 minutes.
717 Antibodies used were vWF (ab6994, abcam) and Alexa Fluor 488 goat anti-rabbit IgG (H+L)
718 (ThermoFisher Scientific). Nuclei were visualised with DAPI. Images were acquired with Nikon
719 A1M confocal laser scanning unit attached to an Eclipse Ti-E microscope.

720

721 To assess the TFPI protein level in conditioned medium, an in-house ELISA was performed.
722 In brief, samples or TFPI recombinant protein standards (ranging from 1000 to 8 ng/mL, 2974-
723 PI. R&D Systems) were coated onto immunoplates (MaxiSorp, Nunc). Following overnight
724 incubation, individual wells were blocked with 1% bovine serum albumin. Antibodies used
725 were TFPI (AF2974, R&D Systems), HRP Rabbit anti-goat IgG (H+L), and Avidin anti-HRP
726 (Invitrogen). The reaction was developed with 3, 3', 5, 5'-tetramethylbenzidine substrate
727 (Invitrogen), stopped by 1M H₂SO₄ and read at 450 nm by a plate reader (FLUOstar Omega,
728 BMG Labtech).

729 To determine the effect of mycolactone on the release of vWF from Weibel-Palade bodies,
730 HDMECs were pre-incubated with DMSO or 7.8ng/mL mycolactone for 24 hours, washed
731 twice with serum free medium, then stimulated with 2 U/mL thrombin for 10 minutes. vWF
732 protein levels were then quantified using an in-house vWF ELISA. Anti-human vWF antibody
733 (A0082, Dako) was coated onto immunoplates overnight at 4°C and blocked with 2% BSA in
734 PBS for 1 hour at room temperature. After blocking, the plate was washed three times with
735 wash buffer (0.05% (v/v) Tween-20 in PBS), samples and standards (NIBSC) ranging from
736 1000 mIU/mL - 4 mIU/mL were added to the wells and the plate was incubated at room
737 temperature for 2 hours. Then, vWF was detected with HRP-conjugated rabbit anti-human
738 vWF (P0226, Dako) followed by 3, 3', 5, 5'-tetramethylbenzidine substrate (Invitrogen),
739 stopped by 1M H₂SO₄ and read at 450 nm by a plate reader (FLUOstar Omega, BMG
740 Labtech).

741

742 **Statistical analysis**

743 Statistical analysis was carried out using GraphPad Prism version 8 (San Diego, USA).
744 Categorical data of analysed vessels was accessed using Chi-square test of association.
745 Yate's correction for continuity was introduced to TF categorical data set as some observed
746 values were below 5. Fibrin intensity per TM⁺ or TM⁻ vessel was assessed using Mann Whitney
747 *U* non-parametric test. Fibrin intensity versus TF intensity or distance to BM per vessel with
748 TF seen outside of BM was assessed using D'Agostino-Pearson normality test; as data set
749 displayed a non-Gaussian distribution, correlation used the method of Spearman. Data
750 otherwise was accessed using a one-way ANOVA and Dunnett's multi-comparison test.
751 Unless otherwise indicated, statistical comparison for *in vitro* assays was vs DMSO-treated
752 controls.

753

754 **Acknowledgments**

755 We would like to thank Lucia Lozano White (University of Surrey) for preparing tissue sections
756 from healthy human skin tissue blocks, Dr Yoshito Kishi (Harvard University, USA) for the gift
757 of synthetic mycolactone A/B, Prof Wolfram Ruf (Scripps Research Institute) and Prof Charles
758 Esmon (Oklahoma Medical Research Foundation) for antibodies against TF and
759 thrombomodulin, respectively. We thank Dr Belinda Hall and Dr Jane Newcombe for critical
760 reading of the manuscript and Prof Mark Wansbrough-Jones (St Georges University of
761 London) for helpful discussions leading to the testing of lymphatic endothelial cells.

762 References

- 763 1. WHO BU. Buruli ulcer. Situation and trends: World Health Organization; 2019
764 [updated 16.09.2019]. Available from:
765 https://www.who.int/gho/neglected_diseases/buruli_ulcer/en/.
- 766 2. Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordey A, Yeboah-Manu D, et al.
767 Buruli Ulcer: a Review of the Current Knowledge. *Curr Trop Med Rep*. 2018;5(4):247-
768 56.
- 769 3. Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, et al. Mapping the
770 global distribution of Buruli ulcer: a systematic review with evidence consensus.
771 *Lancet Glob Health*. 2019;7(7):e912-e22.
- 772 4. Agbenorku P, Edusei A, Agbenorku M, Diby T, Nyador E, Nyamuame G, et al. Buruli-
773 ulcer induced disability in Ghana: a study at Apromase in the Ashanti region. *Plast*
774 *Surg Int*. 2012;2012:752749.
- 775 5. Simpson C, O'Brien DP, McDonald A, Callan P. *Mycobacterium ulcerans* infection:
776 evolution in clinical management. *ANZ J Surg*. 2013;83(7-8):523-6.
- 777 6. O'Brien DP, Friedman ND, McDonald A, Callan P, Hughes A, Walton A, et al. Wound
778 healing: Natural history and risk factors for delay in Australian patients treated with
779 antibiotics for *Mycobacterium ulcerans* disease. *PLoS Negl Trop Dis*.
780 2018;12(3):e0006357.
- 781 7. Lunn HF, Connor DH, Wilks NE, Barnley GR, Kamunvi F, Clancey JK, et al. Buruli
782 (Mycobacterial) Ulceration in Uganda. (a New Focus of Buruli Ulcer in Madi District,
783 Uganda): Report of a Field Study. *East Afr Med J*. 1965;42:275-88.
- 784 8. Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular
785 parasite *Mycobacterium ulcerans* leading to Buruli ulcer. *Lancet Infect Dis*.
786 2009;9(11):699-710.
- 787 9. Ruf MT, Steffen C, Bolz M, Schmid P, Pluschke G. Infiltrating leukocytes surround
788 early Buruli ulcer lesions, but are unable to reach the mycolactone producing
789 mycobacteria. *Virulence*. 2017;8(8):1918-26.
- 790 10. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al.
791 Mycolactone: a polyketide toxin from *Mycobacterium ulcerans* required for virulence.
792 *Science*. 1999;283(5403):854-7.
- 793 11. Pimsler M, Sponsler TA, Meyers WM. Immunosuppressive properties of the soluble
794 toxin from *Mycobacterium ulcerans*. *J Infect Dis*. 1988;157(3):577-80.
- 795 12. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant
796 plasmid-encoded polyketide synthases produce the macrolide toxin of
797 *Mycobacterium ulcerans*. *Proc Natl Acad Sci U S A*. 2004;101(5):1345-9.
- 798 13. George KM, Pascopella L, Welty DM, Small PL. A *Mycobacterium ulcerans* toxin,
799 mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. *Infect*
800 *Immun*. 2000;68(2):877-83.
- 801 14. Ogbechi J, Hall BS, Sbarrato T, Taunton J, Willis AE, Wek RC, et al. Inhibition of
802 Sec61-dependent translocation by mycolactone uncouples the integrated stress
803 response from ER stress, driving cytotoxicity via translational activation of ATF4. *Cell*
804 *Death Dis*. 2018;9(3):397.
- 805 15. Morel JD, Paatero AO, Wei J, Yewdell JW, Guenin-Mace L, Van Haver D, et al.
806 Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive
807 Stress Signature. *Mol Cell Proteomics*. 2018;17(9):1750-65.
- 808 16. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, et al. Selective
809 suppression of dendritic cell functions by *Mycobacterium ulcerans* toxin mycolactone.
810 *J Exp Med*. 2007;204(6):1395-403.
- 811 17. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, et al.
812 Modulation of the host immune response by a transient intracellular stage of
813 *Mycobacterium ulcerans*: the contribution of endogenous mycolactone toxin. *Cell*
814 *Microbiol*. 2005;7(8):1187-96.

- 815 18. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-
816 mediated inhibition of tumor necrosis factor production by macrophages infected with
817 *Mycobacterium ulcerans* has implications for the control of infection. *Infect Immun*.
818 2007;75(8):3979-88.
- 819 19. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. The
820 inhibitory action of *Mycobacterium ulcerans* soluble factor on monocyte/T cell
821 cytokine production and NF-kappa B function. *J Immunol*. 1999;163(7):3928-35.
- 822 20. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits
823 monocyte cytokine production by a posttranscriptional mechanism. *J Immunol*.
824 2009;182(4):2194-202.
- 825 21. Hall BS, Hill K, McKenna M, Ogbечи J, High S, Willis AE, et al. The pathogenic
826 mechanism of the *Mycobacterium ulcerans* virulence factor, mycolactone, depends
827 on blockade of protein translocation into the ER. *PLoS Pathog*.
828 2014;10(4):e1004061.
- 829 22. Gerard SF, Hall BS, Zaki AM, Corfield KA, Mayerhofer PU, Costa C, et al. Structure
830 of the Inhibited State of the Sec Translocon. *Mol Cell*. 2020;79(3):406-15 e7.
- 831 23. Baron L, Paatero AO, Morel JD, Impens F, Guenin-Mace L, Saint-Auret S, et al.
832 Mycolactone subverts immunity by selectively blocking the Sec61 translocon. *J Exp*
833 *Med*. 2016;213(13):2885-96.
- 834 24. McKenna M, Simmonds RE, High S. Mechanistic insights into the inhibition of Sec61-
835 dependent co- and post-translational translocation by mycolactone. *J Cell Sci*.
836 2016;129(7):1404-15.
- 837 25. McKenna M, Simmonds RE, High S. Mycolactone reveals the substrate-driven
838 complexity of Sec61-dependent transmembrane protein biogenesis. *J Cell Sci*.
839 2017;130(7):1307-20.
- 840 26. Grotzke JE, Kozik P, Morel JD, Impens F, Pietrosevoli N, Cresswell P, et al. Sec61
841 blockade by mycolactone inhibits antigen cross-presentation independently of
842 endosome-to-cytosol export. *Proc Natl Acad Sci U S A*. 2017;114(29):E5910-E9.
- 843 27. Lang S, Pfeffer S, Lee PH, Cavalie A, Helms V, Forster F, et al. An Update on Sec61
844 Channel Functions, Mechanisms, and Related Diseases. *Front Physiol*. 2017;8:887.
- 845 28. Ogbечи J, Ruf MT, Hall BS, Bodman-Smith K, Vogel M, Wu HL, et al. Mycolactone-
846 Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with
847 Fibrin Deposition in Buruli Ulcer Lesions. *PLoS Pathog*. 2015;11(7):e1005011.
- 848 29. Cahill PA, Redmond EM. Vascular endothelium - Gatekeeper of vessel health.
849 *Atherosclerosis*. 2016;248:97-109.
- 850 30. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. *BMC Cardiovasc*
851 *Disord*. 2015;15:130.
- 852 31. Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting
853 cascade. *Crit Rev Biochem Mol Biol*. 2015;50(4):326-36.
- 854 32. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The
855 endothelial cell protein C receptor augments protein C activation by the thrombin-
856 thrombomodulin complex. *Proc Natl Acad Sci U S A*. 1996;93(19):10212-6.
- 857 33. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway
858 inhibitor. *Blood*. 2014;123(19):2934-43.
- 859 34. Marcum JA, Atha DH, Fritze LM, Nawroth P, Stern D, Rosenberg RD. Cloned bovine
860 aortic endothelial cells synthesize anticoagulant active heparan sulfate
861 proteoglycan. *J Biol Chem*. 1986;261(16):7507-17.
- 862 35. McCormack JJ, Lopes da Silva M, Ferraro F, Patella F, Cutler DF. Weibel-Palade
863 bodies at a glance. *J Cell Sci*. 2017;130(21):3611-7.
- 864 36. Koerdt S, Rohleder NH, Rommel N, Nobis C, Stoeckelhuber M, Pigorsch S, et al. An
865 expression analysis of markers of radiation-induced skin fibrosis and angiogenesis in
866 wound healing disorders of the head and neck. *Radiat Oncol*. 2015;10:202.
- 867 37. Pham TT, Punsawad C, Glaharn S, De Meyer SF, Viriyavejakul P, Van den Steen
868 PE. Release of endothelial activation markers in lungs of patients with malaria-
869 associated acute respiratory distress syndrome. *Malar J*. 2019;18(1):395.

- 870 38. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and
871 BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in
872 the diagnosis of vascular tumors and comparison with von Willebrand factor. *Mod*
873 *Pathol.* 1994;7(1):82-90.
- 874 39. Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin α IIb β 3:
875 signal transduction, regulation, and its therapeutic targeting. *J Hematol Oncol.*
876 2019;12(1):26.
- 877 40. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and
878 properties of heparin-releasable lipoprotein-associated coagulation inhibitor. *Blood.*
879 1991;78(2):394-400.
- 880 41. Piro O, Broze GJ, Jr. Comparison of cell-surface TFPI α and β . *J Thromb*
881 *Haemost.* 2005;3(12):2677-83.
- 882 42. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander HR, Jr.
883 Interleukin-1 β induced vascular permeability is dependent on induction of
884 endothelial tissue factor (TF) activity. *J Transl Med.* 2005;3:37.
- 885 43. Ji RC. Lymphatic endothelial cells, lymphedematous lymphangiogenesis, and
886 molecular control of edema formation. *Lymphat Res Biol.* 2008;6(3-4):123-37.
- 887 44. Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions:
888 Molecular Regulation in Physiology and Diseases. *Front Physiol.* 2020;11:509.
- 889 45. Foulon M, Robbe-Saule M, Manry J, Esnault L, Boucaud Y, Alcais A, et al.
890 Mycolactone toxin induces an inflammatory response by targeting the IL-1 β
891 pathway: Mechanistic insight into Buruli ulcer pathophysiology. *PLoS Pathog.*
892 2020;16(12):e1009107.
- 893 46. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, et al.
894 Regulation of endothelial thrombomodulin expression by inflammatory cytokines is
895 mediated by activation of nuclear factor-kappa B. *Blood.* 2005;105(10):3910-7.
- 896 47. Antoniak S. The coagulation system in host defense. *Res Pract Thromb Haemost.*
897 2018;2(3):549-57.
- 898 48. Cunningham MW. Pathogenesis of group A streptococcal infections. *Clin Microbiol*
899 *Rev.* 2000;13(3):470-511.
- 900 49. McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes
901 coagulase and von Willebrand factor binding protein to modify the coagulation
902 cascade and establish host infections. *J Innate Immun.* 2012;4(2):141-8.
- 903 50. Moxon CA, Wassmer SC, Milner DA, Jr., Chisala NV, Taylor TE, Seydel KB, et al.
904 Loss of endothelial protein C receptors links coagulation and inflammation to parasite
905 sequestration in cerebral malaria in African children. *Blood.* 2013;122(5):842-51.
- 906 51. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe
907 malaria is associated with parasite binding to endothelial protein C receptor. *Nature.*
908 2013;498(7455):502-5.
- 909 52. diseases WDocont. Treatment of Mycobacterium ulcerans disease (Buruli Ulcer).
910 2012:v, 66 p.
- 911 53. Zavattaro E, Boccafoschi F, Borgogna C, Conca A, Johnson RC, Sopoh GE, et al.
912 Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. *Histopathology.*
913 2012;61(2):224-36.
- 914 54. Bieri R, Scherr N, Ruf MT, Dangy JP, Gersbach P, Gehringer M, et al. The Macrolide
915 Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through
916 Inhibition of mTOR. *ACS Chem Biol.* 2017;12(5):1297-307.
- 917 55. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H,
918 Leadlay PF, et al. Mycolactone activation of Wiskott-Aldrich syndrome proteins
919 underpins Buruli ulcer formation. *J Clin Invest.* 2013;123(4):1501-12.
- 920 56. Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of
921 mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans
922 infection/Buruli ulcer disease. *Cell Microbiol.* 2016;18(1):17-29.

- 923 57. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity
924 of Weibel-Palade bodies in endothelial cells. *Arterioscler Thromb Vasc Biol*.
925 2006;26(5):1002-7.
- 926 58. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional
927 architecture of Weibel-Palade bodies. *Blood*. 2011;117(19):5033-43.
- 928 59. Bauer AT, Suckau J, Frank K, Desch A, Goertz L, Wagner AH, et al. von Willebrand
929 factor fibers promote cancer-associated platelet aggregation in malignant melanoma
930 of mice and humans. *Blood*. 2015;125(20):3153-63.
- 931 60. Kalagara T, Moutsis T, Yang Y, Pappelbaum KI, Farken A, Cladder-Micus L, et al.
932 The endothelial glycocalyx anchors von Willebrand factor fibers to the vascular
933 endothelium. *Blood Adv*. 2018;2(18):2347-57.
- 934 61. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane
935 glycoprotein IIb/IIIa complex during platelet activation. *J Biol Chem*.
936 1985;260(20):11107-14.
- 937 62. McVey JH. The role of the tissue factor pathway in haemostasis and beyond. *Curr*
938 *Opin Hematol*. 2016;23(5):453-61.
- 939 63. Mackman N. The role of tissue factor and factor VIIa in hemostasis. *Anesth Analg*.
940 2009;108(5):1447-52.
- 941 64. Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. *J Atheroscler Thromb*.
942 2015;22(6):543-9.
- 943 65. Kothari H, Keshava S, Vatsyayan R, Mackman N, Rao LV, Pendurthi UR. Role of
944 tissue factor in Mycobacterium tuberculosis-induced inflammation and disease
945 pathogenesis. *PLoS One*. 2014;9(12):e114141.
- 946 66. Kothari H, Rao LV, Vankayalapati R, Pendurthi UR. Mycobacterium tuberculosis
947 infection and tissue factor expression in macrophages. *PLoS One*. 2012;7(9):e45700.
- 948 67. Venkatasubramanian S, Tripathi D, Tucker T, Paidipally P, Cheekatla S, Welch E, et
949 al. Tissue factor expression by myeloid cells contributes to protective immune
950 response against Mycobacterium tuberculosis infection. *Eur J Immunol*.
951 2016;46(2):464-79.
- 952 68. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and
953 sepsis. *Thromb Res*. 2010;125 Suppl 1:S70-3.
- 954 69. Ahamed J, Niessen F, Kurokawa T, Lee YK, Bhattacharjee G, Morrissey JH, et al.
955 Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic
956 domain in endotoxemia. *Blood*. 2007;109(12):5251-9.
- 957 70. Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, Mackman N.
958 Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced
959 cytokine and tissue factor gene expression in monocytes/macrophages. *J Immunol*.
960 2008;180(6):4218-26.
- 961 71. Owens AP, 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, et al.
962 Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic
963 mice and monkeys is inhibited by simvastatin. *J Clin Invest*. 2012;122(2):558-68.
- 964 72. Chakravorty D, Kato Y, Koide N, Sugiyama T, Kawai M, Fukada M, et al. Production
965 of tissue factor in CD14-expressing human umbilical vein endothelial cells by
966 lipopolysaccharide. *FEMS Microbiol Lett*. 1999;178(2):235-9.
- 967 73. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al. Cultured
968 human endothelial cells generate tissue factor in response to endotoxin. *J Clin*
969 *Invest*. 1983;71(6):1893-6.
- 970 74. Pawlinski R, Mackman N. Use of mouse models to study the role of tissue factor in
971 tumor biology. *Semin Thromb Hemost*. 2008;34(2):182-6.
- 972 75. Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. *J*
973 *Intensive Care*. 2015;3(1):2.
- 974 76. Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, Albrecht S, et
975 al. Eosinophils are a major intravascular location for tissue factor storage and
976 exposure. *Blood*. 2007;109(3):995-1002.

- 977 77. Lipets EN, Antonova OA, Shustova ON, Losenkova KV, Mazurov AV, Ataullakhanov
978 FI. Use of Thrombodynamics for revealing the participation of platelet, erythrocyte,
979 endothelial, and monocyte microparticles in coagulation activation and propagation.
980 PLoS One. 2020;15(5):e0227932.
- 981 78. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-
982 derived tissue factor-bearing microparticles are associated with venous
983 thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830-40.
- 984 79. Mendoza CE, Brant EJ, McDermott ML, Froment A, Hu Y, Hogan SL, et al. Elevated
985 Microparticle Tissue Factor Activity Differentiates Patients With Venous
986 Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. Kidney Int
987 Rep. 2019;4(11):1617-29.
- 988 80. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ,
989 Jansen PG, et al. Cell-derived microparticles generated in patients during
990 cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96(10):3534-41.
- 991 81. Khan E, Ambrose NL, Ahnstrom J, Kiprianos AP, Stanford MR, Eleftheriou D, et al. A
992 low balance between microparticles expressing tissue factor pathway inhibitor and
993 tissue factor is associated with thrombosis in Behcet's Syndrome. Sci Rep.
994 2016;6:38104.
- 995 82. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, et al. Induction of
996 microparticle- and cell-associated intravascular tissue factor in human endotoxemia.
997 Blood. 2004;103(12):4545-53.
- 998 83. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of
999 tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy
1000 Immunol. 2009;148(2):170-4.
- 1001 84. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, et al. Evidence
1002 for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun.
1003 2007;75(2):977-87.
- 1004 85. Privratsky JR, Newman PJ. PECAM-1: regulator of endothelial junctional integrity.
1005 Cell Tissue Res. 2014;355(3):607-19.
- 1006 86. Kawamoto E, Okamoto T, Takagi Y, Honda G, Suzuki K, Imai H, et al. LFA-1 and
1007 Mac-1 integrins bind to the serine/threonine-rich domain of thrombomodulin. Biochem
1008 Biophys Res Commun. 2016;473(4):1005-12.
- 1009 87. Pai VC, Lo IC, Huang YW, Tsai IC, Cheng HP, Shi GY, et al. The chondroitin sulfate
1010 moiety mediates thrombomodulin-enhanced adhesion and migration of vascular
1011 smooth muscle cells. J Biomed Sci. 2018;25(1):14.
- 1012 88. Fahey E, Doyle SL. IL-1 Family Cytokine Regulation of Vascular Permeability and
1013 Angiogenesis. Front Immunol. 2019;10:1426.
- 1014 89. Oehlers SH, Cronan MR, Beerman RW, Johnson MG, Huang J, Kontos CD, et al.
1015 Infection-Induced Vascular Permeability Aids Mycobacterial Growth. J Infect Dis.
1016 2017;215(5):813-7.
- 1017 90. Gaertner F, Massberg S. Patrolling the vascular borders: platelets in immunity to
1018 infection and cancer. Nat Rev Immunol. 2019;19(12):747-60.
- 1019 91. Cromer WE, Zawieja SD, Tharakan B, Childs EW, Newell MK, Zawieja DC. The
1020 effects of inflammatory cytokines on lymphatic endothelial barrier function.
1021 Angiogenesis. 2014;17(2):395-406.
- 1022 92. Capela C, Sopoh GE, Houezo JG, Fiodessihoue R, Dossou AD, Costa P, et al.
1023 Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to
1024 Diagnosis on Clinical Forms and Severe Phenotypes. PLoS Negl Trop Dis.
1025 2015;9(9):e0004005.
- 1026 93. Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol.
1027 2007;25(1):9-18.
- 1028 94. Kanga JM, Dion-Laine M, Kacou DE, Menan EI. [Contribution of heparin therapy in
1029 the medical treatment of Buruli ulcer apropos of 1 case]. Bull Soc Pathol Exot.
1030 2001;94(1):32-5.

- 1031 95. Vogel M, Bayi PF, Ruf MT, Bratschi MW, Bolz M, Um Boock A, et al. Local Heat
1032 Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single
1033 Center Non Comparative Clinical Trial. *Clin Infect Dis*. 2016;62(3):342-50.
- 1034 96. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like
1035 peptide bind to human fibrin but not fibrinogen. *Science*. 1983;222(4628):1129-32.
- 1036 97. Kurata R, Futaki S, Nakano I, Fujita F, Tanemura A, Murota H, et al. Three-
1037 dimensional cell shapes and arrangements in human sweat glands as revealed by
1038 whole-mount immunostaining. *PLoS One*. 2017;12(6):e0178709.
- 1039 98. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of
1040 endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human
1041 tissues. *J Histochem Cytochem*. 2006;54(4):385-95.
- 1042 99. Song F, Fidanze S, Benowitz AB, Kishi Y. Total synthesis of the mycolactones. *Org*
1043 *Lett*. 2002;4(4):647-50.

1044 **M. ulcerans confirmed (n = 8)**

Age (years)		12 (7-70)
Type of lesion	Ulcerative	6 (75%)
	Plaque	2 (25%)
WHO category	1	2 (25%)
	2	4 (50%)
	3	2 (25%)
Location	Upper extremities	4 (50%)
	Lower extremities	4 (50%)

1045

1046 **Table 1. Clinical features of analysed Burui ulcer patients.** Category 1: a single lesion <
1047 5 cm in diameter; Category 2: a single lesion 5-15 cm in diameter; Category 3: a single
1048 lesion > 15 cm in diameter, multiple small lesions or facial lesions. Age is presented in
1049 median (with range) and the rest of data are n (%).

1050

1051 **Figure Legends**

1052

1053 **Fig 1. Thrombomodulin expression and fibrin deposition in and around analysed**
1054 **vessels. A.** Vessels in pre-defined areas of punch biopsy samples lacking submacroscopic
1055 appearance of coagulative necrosis (see methods) of 8 BU patients (6 with ulcerated lesions
1056 and 2 with plaque lesions) were tracked by the endothelial cell marker CD31 and perivascular
1057 cell marker SMA, analysed and categorised according to the expression of TM, CD31 and
1058 SMA. The number of vessels in each category per patient was expressed as a percentage of
1059 the total number of the vessels counted for that representative area (listed right). Patients
1060 displaying plaque lesions are indicated with asterisks. The pie chart to the right shows the
1061 overall distribution of each category. **B and C.** The degree of fibrin deposition surrounding
1062 tracked vessels in A. **B** represents the distribution of fibrin scores of thrombomodulin-positive
1063 (TM⁺) and thrombomodulin-negative (TM⁻) vessels. Increasing fibrin scores corresponding to
1064 increasing extension of fibrin staining and are represented by stronger colour (0; no fibrin
1065 staining with 20 µm, 1-3 are fibrin staining in a <20, 20-30 and >30 µm radius, respectively).
1066 The total number of the vessels analysed is shown. **C.** The intensity of fibrin staining within a
1067 20 µm area around each analysed vessel (TM⁻ or TM⁺) was quantified and expressed as
1068 percentage of the total analysed area for all and fibrin positive (Fib⁺) vessels. Data for
1069 individual vessels as well as median and interquartile range is shown. ***; *P* < 0.001.

1070

1071 **Fig 2. Endothelial von Willebrand factor is downregulated in response to mycolactone**
1072 **and redistributes in BU lesions. A-E.** Histological sections stained with antibodies against
1073 vWF (A1-2, B1-3, C6, D6 and E6), platelet glycoprotein CD61 (B4, C5, D5 and E5), SMA (C1,
1074 D1 and E1), CD31 (C2, D2 and E2), TM (C3, D3 and E3) and fibrin (C4, D4 and E4) (positive
1075 staining in brown colour) and counterstained with haematoxylin in a healthy subject (A1-2) and
1076 BU patients (B, C, D and E). Scale bars as indicated. **A-B.** Examples of vessels with different
1077 phenotypes for vWF expression are indicated as follows; black arrows for normal expression,
1078 black arrowheads for reduced expression and black stars for vessels displaying intravascular
1079 vWF staining. Outlined regions in B4 showing distinct CD61 expression patterns in defined
1080 (the upper two; crop panels see C5 & D5) and in necrotic region (the bottom one; crop panel
1081 see E5). **C-D.** Examples of vessels with different phenotypes in pre-defined areas of BU punch
1082 biopsy samples lacking submacroscopic appearance of coagulative necrosis (see methods)
1083 are indicated as follows; purple arrows are SMA⁺CD31⁻TM⁻, blue arrows are SMA⁺CD31⁺TM⁻,
1084 and asterisks are SMA⁺CD31⁺TM⁺ vessels. **E.** An example of a CD61⁺ vessel displaying fibrin
1085 deposition in the necrotic subcutis is indicated with a red arrow. **F.** The overall distribution of

1086 vWF staining patterns in all patients (top panel) and vessels in immune cell-infiltrated regions
1087 (lower panel). The distribution of fibrin scores per vWF staining pattern (i.e. normal,
1088 intravascular and vWF-) is represented by pie charts with the total analysed vessel number
1089 shown. Increasing fibrin scores corresponding to increasing extension of fibrin staining are
1090 represented by darker colour (0; no fibrin staining with 20 μ m, 1-3 are fibrin staining in a <20,
1091 20-30 and >30 μ m radius, respectively). **G & H.** Primary endothelial cells were treated with
1092 10 ng/mL of mycolactone (MYC), 0.02% DMSO or untreated (Ctrl) for 24 hours. **G.** HUVECs
1093 were fixed, permeabilised and immunostained with anti-vWF antibody. vWF-containing
1094 granules are shown in green and nuclei stained with DAPI (blue). Scale bar = 50 μ m. Scatter
1095 plot showing vWF-positive granules per cell in each condition. ****; $P < 0.0001$. **H.** HDMECs
1096 were treated with 2 U/mL thrombin to induce exocytosis of Weibel-Palade bodies. The
1097 concentration of vWF in supernatants was quantified by ELISA. nd, not detected.

1098

1099 **Fig 3. Tissue factor expression is altered in BU patient skin lesion. A-G.** Histological
1100 sections were stained with anti-tissue factor (TF) antibody (A1-2, B5, C5, D5, E5, F5 and G5),
1101 anti-SMA antibody (B1, C1, D1, E1, F1 and G1), anti-CD31 antibody (B2, C2, D2, E2, F2 and
1102 G2), eosin (B3, C3, D3, E3, F3 and G3) or anti-fibrin antibody (B4, C4, D4, E4, F4 and G4)
1103 (positive staining in a brown colour) and counterstained with haematoxylin in healthy subjects
1104 (A) or in pre-defined areas of BU punch biopsy samples lacking submacroscopic appearance
1105 of coagulative necrosis (see methods) (B-G). Scale bar = 50 μ m (20 μ m in the crop panels of
1106 D5, E5 and F5). **B & C.** Red arrows indicate regions of TF staining distant from the vessel
1107 basement membrane (BM). **D.** Asterisks label the same vessel, black arrows in the crop panel
1108 of D5 indicate examples of cells containing punctate structures staining strongly for TF. **E.**
1109 Black arrows indicate examples of cells staining intensively for TF throughout the cells, in
1110 regions where cells stained intensively for eosin in the H&E stain (black arrowhead). **F.** An
1111 orange arrow in the crop panel of F5 indicates an example of the endothelium of a small vessel
1112 stained positively for TF. **G.** Purple arrows indicate examples in a region where multiple small
1113 vessels contained unidentified structures stained positively for TF. **H.** The overall distribution
1114 of vessel phenotypes for TF staining across 8 BU patients. The distribution of fibrin scores
1115 associated with each phenotype are represented as pie charts. Increasing fibrin scores
1116 corresponding to increasing extension of fibrin staining are represented by stronger colour (0;
1117 no fibrin staining with 20 μ m, 1-3 are fibrin staining in a <20, 20-30 and >30 μ m radius,
1118 respectively). The total number of the vessels analysed is shown.

1119

1120 **Fig 4. Mycolactone reduces the expression of tissue factor pathway inhibitor in**
1121 **endothelial cells. A.** HDMECs exposed to 10 ng/mL of mycolactone (MYC) for the indicated
1122 times, 0.02% DMSO or untreated (Ctrl) were lysed and subjected to immunoblotting. TFPI
1123 immunoblot intensity was normalised according to GAPDH and untreated controls. Data from
1124 3 independent experiments are presented (mean \pm SEM). **B.** Supernatant was collected from
1125 cells treated as above for 24 hours, cell debris removed and TFPI was quantified by ELISA.
1126 Values represent the mean of three independent experiments \pm SEM. ***, $P < 0.001$; ****, $P <$
1127 0.0001.

1128

1129 **Fig 5. Extravascular tissue factor (TF) is the primary driver of fibrin deposition in BU**
1130 **lesions, potentially driven by an increase in vascular permeability. A & B.** Correlation
1131 between the abundance of fibrin within a 20 μ m radius of each vessel and the abundance of
1132 tissue factor (TF) in the same radius (**A**) or the distance the TF⁺ signal extended from the
1133 vessel basement membrane (BM) (**B**) for 45 trackable vessels. r is Spearman's rank
1134 correlation coefficient for each data set. **C & D.** Permeability of HDMEC (**C**) or HDLEC (**D**)
1135 monolayers, on inserts with 0.4 and 1 μ m pores respectively, that remained untreated (Ctrl),
1136 or were exposed to 0.02% DMSO, 2.5 or 10 ng/mL mycolactone (MYC), or 100 ng/mL IL-1 β
1137 for 24 hrs. Fluorescence intensity of FITC-dextran in the receiver wells was measured and
1138 presented as a % where 100% is the value obtained from transwell lacking a cell monolayer,
1139 and 0% is untreated control wells. Values represent the mean of three independent
1140 experiments \pm SEM. **, $P < 0.01$; ****, $P < 0.0001$.

1141

1142 **Fig 6. IL-1 β aggravates mycolactone-driven endothelial dysfunction.** HDMECs (**A**) or
1143 HDLECs (**B**) were exposed to different concentrations of mycolactone (MYC), and/or IL-1 β for
1144 24 hours, then lysed and subjected to immunoblotting. TM immunoblot intensity was
1145 normalised according to GAPDH and expressed relative to untreated controls. Mean
1146 expression level from 3 independent experiments are presented as a heatmap where
1147 increased TM loss is represented by a paler colour. **C.** Permeability of HDMEC monolayers
1148 on inserts with 1 μ m pores was quantified after exposure to mycolactone (MYC) and/or IL-1 β
1149 for 24 hours. Fluorescence intensity of FITC-dextran in the receiver wells was measured and
1150 presented as a % where 100% is the value obtained from transwell lacking a cell monolayer,
1151 and 0% is untreated control wells. Values represent the mean of five independent experiments
1152 \pm SEM. *, $P < 0.05$; **, $P < 0.01$; ****, $P < 0.0001$.

1153

1154

1155 **Supporting information Captions**

1156

1157 **S1 Fig. The expression patterns of haemostatic modulators in 8 BU patient skin**
1158 **biopsies.** Histological sections from 8 BU patient punch biopsies stained with eosin (H&E) or
1159 antibody against fibrin, TM, CD61, CD31, SMA, TF and vWF and counterstained with
1160 Haematoxylin. The defined regions identified by a pathologist are outlined in red; vessels in
1161 these areas were tracked and analysed for this study. Immune cell infiltration regions
1162 containing vWF seen in micro vessel lumen outlined in blue. Scale bar = 1 mm.

1163

1164 **S2 Fig. General features of BU patient skin biopsies. A.** Comparison of the staining
1165 patterns with the same anti-SMA or anti-fibrin antibody and conditions seen for the same
1166 punch biopsies at different positions in the tissue block. The “initial section” displays those
1167 performed for Ogbechi et al., 2015 [28], whereas the “serial section” was performed for the
1168 present work. Arrows in different colours label the same vessel identified in different tissue
1169 sections. Scale bar = 500 μ m. Note how the vessel phenotype can vary even over small
1170 distances. **B.** An example of vessel identification and labelling (in colours with individual
1171 number indicated) in serial tissue sections stained with anti-SMA and CD31 antibody. **C.**
1172 Mycobacterial clusters (in purple, indicated with arrows) are identified in histological sections
1173 from 2 BU patient punch biopsies with Ziehl-Neelsen staining. Scar bars as indicated.

1174

1175 **S3 Fig. vWF expression in BU patient specimen and in primary HDMECs. A.** Histological
1176 sections of a healthy subject or BU patient stained with anti-vWF antibody, the respective
1177 isotype control or secondary antibody alone and counterstained with Haematoxylin. **B.**
1178 HDMECs were treated with 10 ng/mL of mycolactone (MYC), 0.02% DMSO or untreated (Ctrl)
1179 for 24 hours. Cells were fixed, permeabilised and immunostained with anti-vWF antibody.
1180 vWF-containing granules are shown in green and nuclei stained with DAPI (blue). Scale bar =
1181 20 μ m.




1182

1183 **S4 Fig. Tissue factor (TF) expression patterns in BU patient specimen. A.** Histological
1184 sections of a healthy subject or BU patient stained with anti-TF antibody, the respective isotype
1185 control or secondary antibody alone and counterstained with Haematoxylin. **B & C.**
1186 Histological sections stained with Haematoxylin and eosin or antibodies against TF and fibrin
1187 and counterstained with Haematoxylin in BU patients. TF-positive activated leukocytes in

1188 necrotic subcutis (**B**) and structures at the edge of the haemorrhagic area (**C**). Scale bar as
1189 indicated.

1190

1191 **S5 Fig. Susceptibility of endothelial cells to mycolactone.** Cell viability of HDLECs,
1192 HDMECs and HUVECs exposed to a variety doses of mycolactone for 5 days was determined
1193 using alamarBlue assay and presented as a % where 100% is the value obtained from cells
1194 treated with solvent control DMSO.

A**B****C****Fig 1**





Fig 2

Healthy subjects



SMA


CD31

H&E

Fibrin

TF

BU patients: No submacroscopic necrosis



H

Tissue Factor vessel phenotype





Fig 3









Fig 4

A**B****C****D**






Fig 6




Fig S1






Fig S2





Fig S3






Fig S4

